Editas Medicine (EDIT) Competitors $2.29 +0.09 (+4.09%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$2.27 -0.02 (-0.87%) As of 08/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. BEAM, CRSP, NTLA, LENZ, TRVI, NRIX, XERS, ORIC, PHAR, and DNAShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), LENZ Therapeutics (LENZ), Trevi Therapeutics (TRVI), Nurix Therapeutics (NRIX), Xeris Biopharma (XERS), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Intellia Therapeutics LENZ Therapeutics Trevi Therapeutics Nurix Therapeutics Xeris Biopharma Oric Pharmaceuticals Pharming Group Ginkgo Bioworks Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings. Do insiders and institutionals believe in BEAM or EDIT? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer BEAM or EDIT? In the previous week, Beam Therapeutics had 20 more articles in the media than Editas Medicine. MarketBeat recorded 28 mentions for Beam Therapeutics and 8 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.03 beat Beam Therapeutics' score of 0.30 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BEAM or EDIT? Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Do analysts rate BEAM or EDIT? Beam Therapeutics currently has a consensus target price of $48.45, indicating a potential upside of 187.39%. Editas Medicine has a consensus target price of $4.70, indicating a potential upside of 105.24%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.31 Is BEAM or EDIT more profitable? Beam Therapeutics has a net margin of -661.31% compared to Editas Medicine's net margin of -701.06%. Beam Therapeutics' return on equity of -43.15% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% Editas Medicine -701.06%-139.24%-63.87% Which has higher earnings & valuation, BEAM or EDIT? Editas Medicine has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M26.85-$376.74M-$4.50-3.75Editas Medicine$35.84M5.35-$237.09M-$3.04-0.75 SummaryBeam Therapeutics beats Editas Medicine on 13 of the 17 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.17M$2.99B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-0.7519.9630.4025.31Price / Sales5.35344.97444.45101.55Price / CashN/A40.7837.7258.50Price / Book1.407.658.306.01Net Income-$237.09M-$54.75M$3.26B$265.10M7 Day Performance-9.49%0.95%1.53%1.39%1 Month Performance-20.49%8.12%3.73%2.43%1 Year Performance-42.61%10.97%41.02%24.74% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.3719 of 5 stars$2.29+4.1%$4.70+105.2%-41.6%$184.17M$35.84M-0.75230News CoveragePositive NewsEarnings ReportBEAMBeam Therapeutics2.5275 of 5 stars$18.70-2.2%$48.75+160.7%-29.7%$1.88B$63.52M-4.06510CRSPCRISPR Therapeutics3.6084 of 5 stars$55.59-6.7%$69.67+25.3%+20.7%$4.80B$37.31M-12.30460Trending NewsAnalyst RevisionNTLAIntellia Therapeutics4.595 of 5 stars$11.58-4.5%$33.37+188.2%-50.1%$1.20B$57.88M-2.21600Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLENZLENZ Therapeutics1.5276 of 5 stars$30.48+3.9%$49.60+62.7%+56.7%$869.35M$5M-16.04110High Trading VolumeTRVITrevi Therapeutics3.0402 of 5 stars$7.41-1.1%$20.88+181.7%+168.5%$869.12MN/A-16.4720News CoverageEarnings ReportAnalyst RevisionNRIXNurix Therapeutics2.3595 of 5 stars$11.31+0.3%$28.87+155.2%-52.8%$864.65M$54.55M-4.33300Positive NewsXERSXeris Biopharma2.8797 of 5 stars$5.48-1.4%$6.25+14.1%+224.4%$856.96M$203.07M-18.27290News CoverageEarnings ReportAnalyst ForecastORICOric Pharmaceuticals4.2045 of 5 stars$9.99+2.6%$18.57+85.9%+15.0%$851.35MN/A-5.3480News CoveragePositive NewsEarnings ReportPHARPharming Group2.7767 of 5 stars$12.250.0%$30.00+144.9%+48.3%$839.18M$297.20M-94.22280Gap DownDNAGinkgo Bioworks0.8881 of 5 stars$14.29+5.0%$8.50-40.5%N/A$836.10M$227.04M-1.56640News CoverageEarnings Report Related Companies and Tools Related Companies Beam Therapeutics Competitors CRISPR Therapeutics Competitors Intellia Therapeutics Competitors LENZ Therapeutics Competitors Trevi Therapeutics Competitors Nurix Therapeutics Competitors Xeris Biopharma Competitors Oric Pharmaceuticals Competitors Pharming Group Competitors Ginkgo Bioworks Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access